Faron Pharmaceuticals Oy has announced the appointment of Yrj Wichmann as the Company's interim Chief Financial Officer (CFO), effective 15 April, 2024. Wichmann, who previously served as the Company's CFO between 2014 and 2019, is an accomplished biotech and financial executive with over 20 years' experience in financing and investment banking. He has most recently served as Senior Vice President, Financing & IR at Faron. The outgoing CFO, James O'Brien, is leaving Faron to pursue another career opportunity.

Faron's CEO, Dr. Markku Jalkanen, expressed confidence in Wichmann's ability to take up the role of Interim CFO, stating, "As a former CFO of this Company and, most recently, our Senior Vice President, Financing & IR, Yrj is well positioned to take up the role of Interim CFO whilst we look for a permanent replacement." Wichmann expressed his priority to advance a financing plan that will secure the company's cash runway and enable the rapid development of bexmarilimab, an important novel immunotherapy in the company's ambitious program.

Outgoing CFO, James O'Brien, expressed his belief in the potential of bexmarilimab and wished the team great success for the future. The company provided contact information for investor inquiries and its financial advisers. Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments.